Current drugs treat bronchospasm and inflammation-to a degree.

​

• They relieve symptoms and are expensive.

​

• Very sick patients require high dosages of steroids

​

• Most of the inhaled drug combinations contain a steroid and act via receptors.

​

• Despite these drugs’ availability, COPD is progressive in many patients and exacerbations still occur.

​​

• Disease progression is not halted.

​

• The presently-used drugs ameliorate symptoms but are not disease modifying.

​

The Artin Bioscience Approach for COPD is a non-steroid dual drug treatment that is expected to stop disease progression, targeting the smoldering steroid and unresponsive inflammation.

​

• This new  treatment is expected to decrease the number of inflammatory cells in the lung, inhibit fibrosis and cause lung vessel dilatation.​​

• This approach is unique as it targets steroid-unresponsive mechanisms of inflammation.​​

• Responding COPD patients should see stabilization of their disease, improved quality of life and a decrease in the number of exacerbations.​​

• The new treatment provides an anti-viral component that benefits patients that commonly are diagnosed with viral infections that cause COPD exacerbations.​​

• Expected to be effective for other respiratory diseases, such as Asthma, Pneumonia, Bronchitis, Cystic Fibrosis, Pulmonary Edema, Interstitial Lung Disease, Sarcoidosis, Acute Respiratory Distress Syndrome (ARDS), Pulmonary and Idiopathic Pulmonary Fibrosis, RSV and Pulmonary Arterial Hypertension (PAH).